TechSci Research’s report, “Tuberculosis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F,” predicts an impressive growth rate for the Global Tuberculosis Therapeutics Market in the forecast period of 2024-2028. The reason for this growth can be attributed to the increase in new treatment options for tuberculosis (TB) over the last few years, which have shown promise in improving patient outcomes and reducing the spread of the disease. Furthermore, the growth of the global tuberculosis treatment market is expected to be further supported by supportive government policies and schemes. One example of a government initiative to develop new TB therapies is the United States’ National Institute of Allergy and Infectious Diseases (NIAID) TB Research Unit. This unit is solely focused on developing new drugs and vaccines for TB, with a particular emphasis on drug-resistant strains of the bacteria. The NIAID TB Research Unit works with researchers from around the world to identify promising drug candidates and test them in clinical trials. Another government initiative is the TB Alliance, which is a non-profit organization created to develop new TB therapies. The TB Alliance is focused on developing drugs that are effective against drug-resistant TB and that can be taken for shorter periods of time than current treatments. The organization has several drugs in clinical trials, including Pretomanid, which was recently approved by the US Food and Drug Administration (FDA) for the treatment of drug-resistant TB.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “Tuberculosis Therapeutics Market.” – https://www.techsciresearch.com/report/tuberculosis-therapeutics-market/14842.html
The growth of the global tuberculosis therapeutics market is impeded by various challenges, one of which is the emergence of drug-resistant strains of the bacteria. Bacteria that cause TB can mutate, leading to resistance against antibiotics used to treat the disease. In 2020, there were approximately 465,000 cases of multidrug-resistant TB (MDR-TB) and an additional 182,000 cases of rifampicin-resistant TB (RR-TB), which is a type of MDR-TB, according to the World Health Organization (WHO). Treating drug-resistant TB is difficult and expensive, and limited treatment options can result in poor patient outcomes. Another challenge is the lengthy treatment duration. Standard treatment for drug-susceptible TB requires a combination of antibiotics for six months, while drug-resistant TB can take up to two years to treat. The long treatment duration can hinder adherence to treatment, leading to treatment failure, disease relapse, and drug resistance development, which could slow down the growth of the global tuberculosis therapeutics market in the future.
The global tuberculosis therapeutics market can be categorized by disease type, therapy, route of administration, dosage form, distribution channel, and region. Based on disease type, the market can be divided into active tuberculosis and latent tuberculosis. The active tuberculosis segment accounted for the majority of the market share in 2022 and is expected to maintain its dominance until 2028 due to the increasing prevalence of active tuberculosis among the population. The latent tuberculosis segment is projected to have the fastest growth rate over the forecast period, as individuals can suffer from the disease without exhibiting symptoms. This type of infection is generally characterized by its presence in the body without causing illness.
The global tuberculosis therapeutics market can be divided into first line therapy and second line therapy by therapy. The first line therapy segment is expected to dominate the market until 2028 due to the development of numerous first line therapeutic drugs, such as isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), streptomycin (SM), and ethambutol (EMB). The second line therapy segment is expected to experience the highest growth rate in the global tuberculosis therapeutics market due to the increasing incidence of drug resistance among the population.
Major companies operating in the Global Tuberculosis Therapeutics Market are:
- AstraZeneca, Plc.
- Johnson & Johnson
- Eli Lilly And Company
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi SA
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
Customers can also request for 10% free customization on this report.
“Governments and companies around the world are working to develop new TB therapies to address the significant challenges posed by this disease. These initiatives are focused on developing drugs that are effective against drug-resistant TB, that can be taken for shorter periods of time than current treatments, and that have fewer side effects, this in turn is further expected to support the growth of global tuberculosis therapeutics market in the coming years” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
Tuberculosis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type (Active Tuberculosis, Latent Tuberculosis), By Therapy (First Line Therapy, Second Line Therapy), By Route of Administration (Oral, Parenteral, Others), By Dosage Form (Tablets, Capsules, Injection, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition”, has evaluated the future growth potential of Tuberculosis Therapeutics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global Tuberculosis Therapeutics Market.
Download Free Sample Report- https://www.techsciresearch.com/sample-report.aspx?cid=14842
Related Reports:
South korea diagnostic labs market
Next generation sequencing kits market
Turkey dietary supplements market
About TechSci Research:
TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and an increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com
Web: https://www.techsciresearch.com